iSpecimen Inc. (ISPC) stock

ISPCNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 7/3028% below fair value

$0.70−0.01 (-1.82%)

Close on Nov 12, 2026Market cap $1.75MP/E –Yield –

iSpecimen price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

iSpecimen's price to sales ratio was 2.3× on Nov 11, 2026, against 1.2× a year earlier. Over the last 5 years it ranged from 0.2× to 5.0×, with a median of 1.0×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	2.3×	+1.6
2025	Dec 31, 2025	0.8×	+0.5
2024	Dec 31, 2024	0.2×	−0.2
2023	Dec 29, 2023	0.4×	−0.8
2022	Dec 30, 2022	1.2×	−3.6
2021	Dec 31, 2021	4.8×	–

Where these numbers come from

Parsed from the XBRL in iSpecimen's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-40 reverse split on Apr 28, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ISPC.

Compare: ISPC vs ONMD · ISPC vs ABSI · ISPC vs CBIH · ISPC vs MWAI · ISPC vs AIDX

Revenue growth-92.1% · median -47.2%

Gross margin-98.0% · median 5.0%

Operating margin-2020.0% · median -695.7%

Net margin-2449.0% · median -584.2%

Company	Revenue	Growth
ABSI	$1.49M	-47.2%
ONMD	$1.46M	+216.5%
ISPC	$466.30K	-92.1%
CBIH	$123.63K	-64.1%
MWAI	–	–
AIDX	–	–

Company

Exchange: Nasdaq
Industry: Services-Commercial Physical & Biological Research
Fiscal year ends: December 31
Employees: 53
Held by institutions: 2.3%
Auditor: Bush & Associates CPA LLC
SEC CIK: 1558569

Advertisement
300 × 250

See a number that looks wrong?